Turkmenistan Medical Device Registration Fees: Cost Structure and Budgeting Approach

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

The fees in Turkmenistan consist of 3 blocks, and the nature of the three blocks is entirely different:

  1. The state fee — paid according to the payment notice issued by the competent authority, and usually not refundable in the event of rejection;
  2. TDS mandatory certification fees — arising under the Certification Law, per batch or per contract;
  3. Document chain costs — notarization, certification by the Ministry of Justice, certification by the Ministry of Foreign Affairs, embassy or consular legalization, and translation.

We have not been able to obtain the official fee schedule; therefore no amount figures are given, only the 3-block structure and the budgeting method. This restraint is deliberate: quoting unverifiable numbers creates false precision, while the structure alone is already sufficient to build a defensible budget and to interrogate quotations from service providers.

2. Legal basis

Legal instrumentReference or numberPublication dateProvisions
Law of Turkmenistan on the Supply of MedicinesNo. 319-VJanuary 12, 2016State fees for national registration and their payment
Certification Law of TurkmenistanNo public numberCurrent versionFees for mandatory certification
Hague Convention Abolishing Legalization of 1961None (international convention)Member list, January 2025 editionTurkmenistan is not a member (source of consular legalization costs)

3. Expert insights

Insight 1: The state fee arises only after the preliminary review, and this timing matters.

As article 11 has explained, the sequence of the procedure is: submission, preliminary review, issuance of the payment notice, payment, and subsequent review. This means the state fee is not an entrance fee but a fee charged after the preliminary examination has been passed. The non-refundable rule nevertheless remains in force, so the quality of the dossier directly determines whether this money is wasted. The timing also has a cash-flow implication: fees arrive at an unpredictable point within the review period rather than at submission, so the budget line should be released with flexibility and the finance function told that the invoice date is set by the authority, not by the applicant.

Insight 2: Usually not refundable is the largest sunk risk of this project.

That fees are not refunded when an application is rejected is the explicit spirit of the system. Under such a rule, the benefit of getting the dossier right the first time far exceeds the savings from economizing on preparation costs. This is also why we repeatedly stress the acceptance threshold of the preliminary review. A useful way to frame the decision internally: every hour of senior review time spent before submission is cheap insurance against a fee that cannot be recovered and a calendar that restarts from zero. Boards approve budgets more readily when the non-refundable exposure is quantified against the preparation spend.

Insight 3: Consular legalization costs are the block that is systematically underestimated.

As article 15 has explained, Turkmenistan is the only post-Soviet state that has not joined the Hague Convention Abolishing Legalization. Every document requiring legalization must pass through the four stages of notarization, the Ministry of Justice, the Ministry of Foreign Affairs, and the embassy or consulate. The number of documents multiplied by four stages of fees and by round-trip time becomes conspicuous in a project with a dozen or more documents. The multiplication is easy to forget because each stage looks small in isolation; only the aggregate, computed late, reveals that legalization can rival the state fee itself in a document-heavy application.

Insight 4: Certification fees are a variable cost incurred with every shipment.

Unlike the registration fee, which arises once in 5 years, TDS certification fees arise per batch or per contract. When preparing the annual budget, this block should be booked as a variable cost, not as a one-off investment. The distinction changes behavior: variable costs per consignment belong in the landed-cost calculation of every order, alongside freight and duties, so that pricing and tender quotations absorb them automatically. Companies that misclassify them as one-off setup costs systematically underprice repeat business in Turkmenistan.

Insight 5: Translation costs vary with the language strategy.

As article 13 has explained, Russian is the mandatory language. Documents requiring Russian translation include the cover letter, the application form, the certificate of pharmaceutical product or registration certificate, the GMP certificate, the instructions for use, and quality control methods. The broader the language strategy, the higher the translation cost; we recommend Russian as the primary language and Turkmen as needed, without pointless full translation into all three languages. Translation quality deserves the same attention as volume: terminology consistency across the dossier, verified by a single translator or a glossary, prevents the reviewer-facing inconsistencies that trigger avoidable questions.

4. Practical recommendations

  1. Budget along the three blocks: state fee, certification fees, and document chain costs, omitting nothing.
  2. Book certification fees per batch or contract as a variable cost and do not assume a one-off expense.
  3. Estimate consular legalization costs and time as the number of documents multiplied by four stages.
  4. Adopt Russian as the primary language and Turkmen as needed to control translation cost.
  5. Treat getting the dossier right the first time as the core instrument against the sunk risk of the state fee.

5. Verification checklist

  • □ The budget covers the three cost blocks.
  • □ Certification fees have been booked in the annual budget as a variable cost.
  • □ Consular legalization costs have been estimated as the number of documents multiplied by four stages.
  • □ The language strategy has been set with Russian as the primary language.
  • □ The dossier quality self-check has been adopted as the response to the sunk risk of the state fee.

Regulatory information verified as of October 30, 2026. The content cited in this document has been checked against the Law of Turkmenistan on the Supply of Medicines No. 319-V (January 12, 2016; the state fee for national registration is paid per notice and is usually not refundable upon rejection), the Certification Law (current version), and the January 2025 edition of the member list of the Hague Convention Abolishing Legalization of 1961 (Turkmenistan is not a member; source of the consular legalization chain costs); the specific fee schedule, amounts, and refund rules have not been obtained in official text, this document gives no amount figures, and the payment notice issued by the competent authority at the material time prevails.

  • Local resources in Turkmenistan: GRZAN can coordinate licensed local import entities and authorized representative resources, covering national registration submissions, the consular legalization chain for documents, sample delivery, interface with mandatory TDS certification, and customs clearance support.
  • Service capabilities: classification assessment, registration pathway selection, national-format dossier writing, notarization and consular legalization, preparation of test and stability documentation, organization of GMP and ISO 13485 evidence, variations and renewal, vigilance and post-market maintenance.
  • Contact: info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail